Andrea Gallamini, EHA 2019 – Three-year Update of the ECHELON-1 Study

We are joined by Andrea Gallamini, at EHA 2019 to discuss his presentation on frontline brentuximab vedotin with chemotherapy for stage 3/4 classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study.

Questions
1. Could you tell us a little about the ECHELON-1 study and its findings? (0:05)
2. What have we learned from the 3-year update of this study? (1:31)
3. Which patients are most likely to respond to this approach and in which patients is it contraindicated? (2:15)
4. How is the role of brentuximab vedotin likely to further involve in the treatment of classical Hodgkin lymphoma? (3:29)
5. How can the issue of brentuximab vedotin resistance be overcome? (4:18)

Andrea Gallamini has no conflicts of interest to declare in relation to this video.

Filmed at the European Hematology Association (EHA) 24th congress 2019, Amsterdam, Netherlands.

touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.